Search
moon
sun
๐ŸŒฉ๏ธ

T171. Seizures and status epilepticus in adults

A. Introduction and pathophysiology

โ€ข
Seizure (๊ฒฝ๋ จ) : Brain neuron์˜ ๋น„์ •์ƒ์ ์ธ ์ „๊ธฐ์  ํ™œ๋™์œผ๋กœ ์ธํ•ด ์•ผ๊ธฐ๋˜๋Š” ์ผ๋ จ์˜ ์‹ ๊ฒฝํ•™์  ๊ธฐ๋Šฅ ์ด์ƒ
โ€ข
Brain neuron์˜ ์ „๊ธฐ์  ํ™œ๋™์€ glutaminergic (excitatory) and ฮณ-aminobutyric acid (inhibitory) activity์˜ ํ•ญ์ƒ์„ฑ์— ์˜ํ•œ ๊ฒƒ์œผ๋กœ ์ƒ๊ฐ๋˜๋ฉฐ, seizure๋Š” ๋ถ€์ ์ ˆํ•œ excitatory activity ์ƒํƒœ์—์„œ ๋‚˜ํƒ€๋‚˜๋Š” ์ž„์ƒ ์ฆ์ƒ์„ ๋งํ•œ๋‹ค.

A1. Epilepsy (๋‡Œ์ „์ฆ)

โ€ข
๊ฐ€์—ญ์  ์›์ธ (alcohol withdrawal, toxin, hypoglycemia, metabolic derangement)์ด ์•„๋‹Œ ๊ฒƒ์œผ๋กœ ์œ ๋ฐœ๋œ recurrent seizure๋กœ, seizure threshold๊ฐ€ ๋‚ฎ์•„์ ธ brain neuron์ด fixed, excitatory condition์— ๋†“์ด๊ฒŒ ๋œ ๊ฒƒ์„ ๋งํ•œ๋‹ค.

A2. Primary (or idiopathic) seizure

โ€ข
Seizure์˜ ๋ช…ํ™•ํ•œ ์œ ๋ฐœ ์›์ธ์ด ํ™•์ธ๋˜์ง€ ์•Š์€ ๊ฒฝ์šฐ

A3. Secondary(or symptomatic) seizure

โ€ข
ํ™•์ธ ๊ฐ€๋Šฅํ•œ ์‹ ๊ฒฝํ•™์  ๋ฌธ์ œ(ex. mass lesion, previous head injury, or stroke)์— ์˜ํ•ด ์œ ๋ฐœ๋œ ๊ฒฝ์šฐ

A4. Reactive seizure

(1) ์œ ๋ฐœ ์ธ์ž

โ€ข
์ €ํ˜ˆ๋‹น(m/c)
โ€ข
๋‡Œ์˜ ์ „๊ธฐ์ž๊ทน
โ€ข
convulsant potentiating drugs
โ€ข
Profound metabolic disturbances
โ€ข
significant head trauma etc.

(2) ์ผ๋ฐ˜์ ์œผ๋กœ self-limited์–‘์ƒ ๋ณด์ž„

โ‡’ seizure disorder, epilepsy๋กœ ๊ฐ„์ฃผํ•˜์ง€ ์•Š๋Š”๋‹ค

A5. Provoked vs Unprovoked seizure

: 7์ผ ์ด๋‚ด์— ์œ ๋ฐœ ์š”์ธ์ด ์œ  vs ๋ฌด

A6. Status Epilepticus

: Seizure activity 5๋ถ„ ์ด์ƒ ์ง€์† or ์ค‘๊ฐ„์— ์˜์‹ ํšŒ๋ณต ์—†์ด 2๋ฒˆ ์ด์ƒ seizure๋ฅผ ์ง€์†ํ•˜๋Š” ๊ฒฝ์šฐ

A7. Refractory status epilepticus

: ์ ์ ˆํ•œ ์šฉ๋Ÿ‰์˜ IV antiepileptic agents๋ฅผ 2๊ฐœ ์ด์ƒ ์“ฐ๊ณ ๋„ seizure๊ฐ€ ๋ฉˆ์ถ”์ง€ ์•Š๊ณ  ์ง€์†๋˜๋Š” ๊ฒฝ์šฐ

B. Seizure classification

B1. Generalized seizure

(1) Tonic-clonic seizure (grand mal)

โ€ข
LOC ๋™๋ฐ˜. ์ „ํ˜•์  ์–‘์ƒ. ๋ชธํ†ต๊ณผ ์‚ฌ์ง€๊ฐ€ ๊ตณ์œผ๋ฉด์„œ ์‹ ์ „๋จ
โ€ข
Rigid phase : ๊ฐ€๋” ๋ฌดํ˜ธํก. ์ฒญ์ƒ‰์ฆ. ๋ฐฐ๋‡จ. ๊ตฌํ† 
โ€ข
Clonic phase : ๋Œ€์นญ์ ์ด๊ณ  ๋ฆฌ๋“ฌ ์žˆ๋Š” jerking์ด ์ผ์–ด๋‚จ
โ€ข
60~90์ดˆ ๊ฐ€๋Ÿ‰ ์ง€์† ํ›„ ํ˜ผ๋ˆ (postictal confusion) ๋ฐ ํ”ผ๋กœ ์ˆ˜ ์‹œ๊ฐ„ ์ง€์† ๊ฐ€๋Šฅ

(2) Absence seizure (Petit mal)

โ€ข
์ž๊ทน์— ๋ฐ˜์‘ ์—†๋Š” ์ˆ˜ ์ดˆ ๊ฐ„์˜ ์˜์‹ ์†Œ์‹ค์ด ์œ ์ผํ•œ ์ฆ์ƒ. (์ƒํ™ฉ์„ ๊ธฐ์–ต ๋ชปํ•œ๋‹ค)
โ€ข
์ž์„ธ ๋ณ€ํ™” ์—†๋Š” ์ƒํƒœ๋กœ ํ—ˆ๊ณต ์‘์‹œํ•˜๊ฑฐ๋‚˜ ๋ˆˆ๊บผํ’€ ์”ฐ๋ฃฉ๊ฑฐ๋ฆผ
โ€ข
๋ฐœ์ž‘ ํ›„ ํ˜ผ๋ˆ ์ฆ์ƒ์ด ์—†๋‹ค
โ€ข
ํ•™๋ น๊ธฐ ์•„๋™์—์„œ ํ”ํ•˜๋ฉฐ, ์ผ๋ฐ˜์ ์œผ๋กœ ์„ฑ์ธ์ด ๋˜๋ฉด์„œ ์‚ฌ๋ผ์ง cf. ์„ฑ์ธ์˜ ๊ฒฝ์šฐ ๋น„์Šทํ•œ ์–‘์ƒ์˜ seizure๋ผ๊ณ  ํ•˜๋”๋ผ๋„ minor complex partial seizure๋กœ ๋ถ„๋ฅ˜ํ•จ

(3) Others(myoclonic, tonic, clonic, atonic)

B2. Partial (Focal) seizure

โ€ข
Cerebral localized region ์—์„œ ์‹œ์ž‘๋˜๋Š” discharge๋กœ ์ธํ•œ ๊ฒฝ๋ จ

(1) Simple partial focal seizure

โ€ข
LOC ์—†์Œ . Localized seizure (์ƒํ™ฉ ๊ธฐ์–ต)
โ€ข
Unilateral tonic-clonic movement, Visual sx., ํ›„๊ฐ/๋ฏธ๊ฐ hallucination โ†’ โ€˜Aurasโ€™ : โ€˜ โ€™ ์ด์ฐจ์„ฑ ์ „์‹ ํ™” ๋กœ ํ™•๋Œ€๋  ์ˆ˜ ์žˆ๋‹ค.

(2) Complex partial seizure (= Temporal lobe seizure, psychomotor seizure)

โ€ข
์˜์‹ ๋ณ€ํ™”๊ฐ€ ๋™๋ฐ˜.
โ€ข
Temporal lobe . ์—์„œ ๋งŽ์ด ๊ธฐ์ธ
โ€ข
์ฆ์ƒ : autism (์ž…๋ง› ๋‹ค์‹œ๊ธฐ, ๋ฒ„ํŠผ ๋งŒ์ง€์ž‘๊ฑฐ๋ฆฌ๊ธฐ), Visceral symptoms (ex-๋ช…์น˜๋ถ€ ๋ถˆํŽธ๊ฐ) : Hallucination, Memory disturbances, Distorted perception, Affective disorder โ†’ Psychosis๋กœ ์ž์ฃผ ์˜ค์ง„๋œ๋‹ค.
โ€ข
Partial seizure์˜ ์ด์ฐจ์„ฑ ์ „์‹ ํ™” : Focal discharge โ†’ spread to both hemisphere : General seizure์™€ ์œ ์‚ฌํ•˜๊ฒŒ ๋ณด์ž„ : Focal vs general seizure์˜ ์ •ํ™•ํ•œ ์ง„๋‹จ์€ EEG๋ฅผ ํ†ตํ•ด ์ด๋ฃจ์–ด์ง„๋‹ค

B3. Unclassified

C. Clinical Features

C1. History

(1) True seizure ์—ฌ๋ถ€ ํ™•์ธ์ด ๊ฐ€์žฅ ์ค‘์š”. ๋ชฉ๊ฒฉ์ž์—๊ฒŒ ์–‘์ƒ์„ ์ •ํ™•ํžˆ ํŒŒ์•…ํ•œ๋‹ค
โ€ข
๊ฒฝ๋ จ์˜ ์–‘์ƒ : Aura ์—ฌ๋ถ€, ๊ฐ‘์ž๊ธฐ ํ˜น์€ ์„œ์„œํžˆ ๋ฐœ์ƒํ–ˆ๋Š”์ง€, motor activity๊ฐ€ ์ง„ํ–‰ํ–ˆ๋Š”์ง€, ๋ณ€/์š”์‹ค๊ธˆ, oral injury, ๊ตญ์†Œ์  vs ์ „์‹ ์ , ๋Œ€์นญ์ , Duration, Postictal sx. ์—ฌ๋ถ€
Known epilepsy pt.์—์„œ ๋™์ผ ์–‘์ƒ์˜ ๊ฒฝ๋ จ ๋ฐœ์ƒ ์‹œ
First onset ํ™˜์ž

C2. Physical Examination

โ€ข
Vital sign ํ™•์ธ
โ€ข
ํ™˜์ž ์˜์‹ ์ˆ˜์ค€ ๊ณ„์† ํ™•์ธ
โ€ข
๊ฒฝ๋ จ์œผ๋กœ ์ธํ•œ ์™ธ์ƒ ์œ ๋ฌด ํ™•์ธ (head, spine, post. shoulder dislocation)
โ€ข
Todd paralysis : ๊ฒฝ๋ จ ํ›„ ๋ฐœ์ƒํ•œ ์ผ์‹œ์  ๊ตญ์†Œ ์‹ ๊ฒฝํ•™์  ๊ฒฐ์†, ์ฃผ๋กœ unilateral, 48์‹œ๊ฐ„ ๋‚ด ํ˜ธ์ „

D. Diagnosis

D1. Differential diagnosis

(1) Syncope

โ€ข
์ „๊ตฌ ์ฆ์ƒ์ด ์žˆ๋‹ค (Cardiac syncope ์€ ์˜ˆ์™ธ)
โ€ข
๋‘ํ†ต, ๋ฐœํ•œ, ์˜ค์‹ฌ, tunnel vision (ํ„ฐ๋„ ์†์—์„œ ํ„ฐ๋„ ์ž…๊ตฌ๋ฅผ ๋ฐ”๋ผ๋ณด๋Š” ๋ชจ์–‘์œผ๋กœ ์‹œ์•ผ๊ฐ€ ์ œํ•œ)
โ€ข
๋น ๋ฅธ ํšŒ๋ณต, postictal ์—†์Œ
โ€ข
(ยฑ) Injury, brief tonic-clonic, ์‹ค๊ธˆ

(2) Pseudoseizure

โ€ข
๋ชฉ๊ฒฉ์ž๊ฐ€ ์žˆ์„ ๋•Œ๋งŒ ๋˜๋Š” ํฅ๋ถ„ํ–ˆ์„ ๋•Œ๋งŒ ์ƒ๊ธฐ๋ฉด ์˜์‹ฌ
โ€ข
Attack ์ค‘์— ํ•ด๋กœ์šด ์ž๊ทน์„ ์ฃผ๋ฉด ๋ฐฉ์–ดํ•˜๋ ค ํ•œ๋‹ค
โ€ข
๊ณ ๊ฐœ ์ขŒ์šฐ๋กœ ๋„๋ฆฌ๋„๋ฆฌ/ ํŒ”๋‹ค๋ฆฌ๊ฐ€ symmetric ํ•˜์ง€ ์•Š๊ณ  ๋งˆ๊ตฌ ์›€์ง์ž„
โ€ข
์‹ค๊ธˆ, ์†์ƒ, ์ฆ์ƒ ํ›„ ํ˜ผ๋ˆ ๋“ฑ์ด ๊ฑฐ์˜ ์—†๋‹ค
โ€ข
์ •ํ™•ํ•œ ์ง„๋‹จ์€ video monitoring + EEG
โ€ข
Lactic acidosis (-)

(3) Hyperventilation SD

โ€ข
์„œ์„œํžˆ ๋ฐœ์ƒ (๋ถˆ์•ˆ, ์ž… ์ฃผ์œ„ ๊ฐ๊ฐ ๋–จ์–ด์ง€๋Š” ๋А๋‚Œ, ์งง์€ ์ˆจ) โ†’ Involuntary spasm (ํŠนํžˆ ์†์˜ ์—ฐ์ถ•)
โ€ข
(ยฑ) LOC
โ€ข
Postictal sx.์€ ๊ฑฐ์˜ ์—†๋‹ค.

(4) Movement disorder

โ€ข
Dystonia, chorea, myoclonic jerk, tremor, ํ‹ฑ (์˜์‹ ์†Œ์‹ค ์—†์œผ๋ฉฐ ์ž๊ฐ€ ํ†ต์ œ ๊ฐ€๋Šฅํ•œ ๊ฒฝ์šฐ ์žˆ์Œ)

(5) Migraine HA

โ€ข
Aura ๋™๋ฐ˜(์‹œ์•ผ ๋ฒˆ์ฉ์ž„)
โ€ข
Focal neurologic sx. ๋™๋ฐ˜ ๊ฐ€๋Šฅ (๋™์ธก๋ฐ˜๋งน - homonymous hemianopsia- or hemiparesis)

D2. Laboratory testing

(1) Known epilepsy ์ธ ๊ฒฝ์šฐ

: Single unprovocatedํ•œ ๊ฒฝ์šฐ๋ผ๋ฉด, ํ˜ˆ๋‹น, AED level ๋งŒ ํ•„์ˆ˜ ๊ฒ€์‚ฌ์— ํ•ด๋‹น

(2) First onset ์ธ ๊ฒฝ์šฐ

โ€ข
ํ˜ˆ๋‹น, Lactate, ๊ธฐ๋ณธ metabolic panel, ์ „ํ•ด์ง•,, Ca/Mg, hCG, toxicology
โ€ข
AED level ๋„ ๊ณ ๋ ค

(3) Lactate, prolactin level

โ†’ True seizure ๊ฐ๋ณ„์— ์œ ์šฉ
โ€ข
Lactate : ํ˜ธํก๋ฌธ์ œ โ†’ ํ˜๊ธฐ์„ฑ ๋Œ€์‚ฌ โ†’ Lactic acid ์ƒ์„ฑ โ†’ High anion gap metabolic acidosis : 30 ๋Œ€๋ถ€๋ถ„ ๋ถ„ ์ด๋‚ด ํ˜ธ์ „
โ€ข
Prolactin level : ๊ฒฝ๋ จ ์งํ›„ 15~60๋ถ„ ๋™์•ˆ ์ƒ์Šน

D3. Imaging

(1) Brain CT

โ‘  First onset pt. : seizure pattern์ด ๋ณ€ํ•œ ํ™˜์ž๋Š” brain CT๋ฅผ ์ฐ์–ด์•ผ ํ•œ๋‹ค โ‘ก Non-contrast brain CT scan์ด appropriateํ•œ screening tool์ด๋‹ค โ‘ข Metabolic cause๊ฐ€ ์žˆ๋”๋ผ๋„ CT scan์„ ๊ณ ๋ คํ•˜๋Š” ๊ฒƒ์ด ์ข‹๋‹ค โ‘ฃ ์ถ”ํ›„ Contrast CT๋‚˜ MRI ๋“ฑ ํ•„์š”ํ•  ์ˆ˜ ์žˆ์Œ (์‹ ๊ฒฝ๊ณผ ํ˜‘์ง„์œผ๋กœ ๊ฒฐ์ •. ER์—์„œ CT-angio๊นŒ์ง€ ํ•„์š”ํ•œ ๊ฒฝ์šฐ๋Š” ๊ฑฐ์˜ ์—†๋‹ค

(2) shoulder, c-spine image

โ€ข
์†์ƒ ์˜์‹ฌ ์‹œ ์˜์‹ฌ ์‹œ ๋“ฑ ๊ณ ๋ ค

(3) CXR

โ€ข
์ข…์–‘, ํก์ž…, ๊ฐ์—ผ

D4. Lumbar puncture

(1) ์—ด ๋‚˜๊ฑฐ๋‚˜ ๋ฉด์—ญ ์ €ํ•˜ ์ƒํƒœ์ผ ๋•Œ (2) CT์—์„œ๋Š” ์•ˆ ๋ณด์ด์ง€๋งŒ SAH ์˜์‹ฌ๋  ๋•Œ

D5. EEG

E. Treatment

โ€ข
Updated algorithm Emphases early escalation to anaesthetics to achieve seizure termination Rather than another second-line anti-epileptic drug Within 30-60min of seizure onset To minimize neuronal injury and pharmaco-resistance, which increase with prolonged seizure duration

E1. Patients with active seizure

โ€ข
์˜†์œผ๋กœ ๋Œ๋ ค์„œ ํก์ธ๋˜์ง€ ์•Š๋„๋ก
โ€ข
Ventilation ์–ต์ง€๋กœ ์‹œํ‚ฌ ํ•„์š” ์—†๊ณ , ๋ฉˆ์ถค ๋’ค ๊ธฐ๋„ํ™•์ธ + Airway ํ™•๋ณด
โ€ข
๋Œ€๋ถ€๋ถ„ 5๋ถ„ ์ด๋‚ด ๋ฉˆ์ถค / 5๋ถ„ ์ด๋‚ด ํ•ฉ๋ณ‘์ฆ ์—†๋Š” ๊ฒฝ๋ จ์—๋Š” AED ๋น„์ถ”์ฒœ (์˜์‹ํšŒ๋ณต ์ €ํ•ด)

E2. Patients with a history of seizure

โ€ข
๊ฐ€๋Šฅํ•œ ์ด‰๋ฐœ์š”์ธ ์ฐพ๊ธฐ / AED ํ•œ๋ฒˆ๋งŒ skip ํ•ด๋„ ๊ฒฝ๋ จ ๊ฐ€๋Šฅ
โ€ข
AED level์ด ๋งŽ์ด ๋‚ฎ์€ ๊ฒฝ์šฐ : Loading dose or supplement dose โ†’ Regular regimen ํˆฌ์•ฝ (Loading ์ „์— serum AED level check ํ•  ๊ฒƒ)
โ€ข
AED level ์ ์ ˆ + ํ•œ ๋ฒˆ ๋ฐœ์ƒ (์ด์ „๊ณผ ํŒจํ„ด, frequency ๋™์ผ) : ํŠน์ •ํ•œ ์ฒ˜์น˜๋Š” ํ•„์š”ํ•˜์ง€ ์•Š๋‹ค
โ€ข
AED level ์ธก์ • ์–ด๋ ต๊ณ  noncompliance ์˜ˆ์ƒ ์‹œ : ํ‡ด์› ์ „ ED์—์„œ usual dose ํˆฌ์•ฝ (e.g Levetiracetam, Lacosamide)
โ€ข
Loading dose ์‹œ PO/IV ๋น„๊ต ์—ฐ๊ตฌ ์•„์ง ์—†์Œ ๋‹ค๋งŒ phenytoin์˜ ๊ฒฝ์šฐ 20mg/kg๋ฅผ PO๋Š” #3๋กœ ๋ณต์šฉ ํ•˜์ง€๋งŒ IV๋Š” single dose๋กœ ์ฃผ๊ธฐ ๋•Œ๋ฌธ์— ED์—์„œ๋Š” IV๊ฐ€ ์ ์ ˆ

E3. Patients with a first unprovoked seizure

โ€ข
์ข…๋ฃŒ ํ›„ neurologic defecit์ด ์—†๋‹ค๋ฉด AED ๋ฐ ์ž…์› ํ•„์š” ์—†์Œ.
โ€ข
EEG ๋ฐ ์•…ํ™” ์ธ์ž๊ฐ€ ๊ฐ€์žฅ ์ค‘์š”ํ•œ ์˜ˆ์ธก ์ธ์ž cf) ์ด์ฐจ์„ฑ (provoked) ๊ฒฝ๋ จ์€ ์žฌ๋ฐœ ๊ฐ€๋Šฅ์„ฑ์ด ๋†’์•„ ๋ณดํ†ต ์ž…์› ํ•„์š”
โ€ข
AED์˜ ์‚ฌ์šฉ ์—ฌ๋ถ€๋Š” ์ดํ›„ ์™ธ๋ž˜์—์„œ MRI๋‚˜ EEG ํ›„ ๊ณ ๋ คํ•˜๋„๋ก ํ•œ๋‹ค.
Carmazepine CT 200mg tab 1T
Rivotril 0.5mg tab (clonazepam) 1T
Fycompa susp 0.5 mg/mL 8mL

F. Status epilepticus

F1. ์ž„์ƒ ์–‘์ƒ

(1) 5 ๋ถ„ ์ด์ƒ or 2๋ฒˆ ์ด์ƒ ๊ฒฝ๋ จ ์‚ฌ์ด์— ์˜์‹ ํšŒ๋ณต ์—†์„ ๋•Œ (2) ๊ฐ€์žฅ ํ”ํ•œ ์›์ธ์€ antiepileptic level์ด ์น˜๋ฃŒ๋†๋„ ์ดํ•˜์ผ ๋•Œ (3) Seizure๊ฐ€ 5๋ถ„ ์ด์ƒ ์ง€์† ์‹œ ์‘๊ธ‰์น˜๋ฃŒ ํ•„์š” (์‹ ๊ฒฝ ์†์ƒ ๊ฐ€๋Šฅ์„ฑ ๋†’์•„์ง) (4) 20~30๋ถ„ ์ด์ƒ ๊ฒฝ๊ณผ ์‹œ : ์ €ํ˜ˆ์••, ์ €์‚ฐ์†Œ์ฆ, ๋Œ€์‚ฌ์„ฑ์‚ฐ์ฆ, ๊ณ ์ฒด์˜จ์ฆ, ์ €ํ˜ˆ๋‹น ๋“ฑ ์œ ๋ฐœ
โ€ข
Nonconvulsive status epilepticus (1) Seizure like activity ์—†์ด ์˜์‹ ์ €ํ•˜ ์ง€์† (2) Prolonged post ictal status subtle motor signs(twitching, blinking, eye deviation, fluctuating alteration in mental status, unexplained stupor or confusion in elderly) ์‹œ ์˜์‹ฌ (3) continuous nonconvulsive seizure that lasts >30 min or Multiple Non convulsive seizure with period> 30 min & Sensory, motor, Cognitive fx not fully recovered (4) EEG๋กœ confirmํ•œ๋‹ค.
โ€ข
Epilepsia partialis continua ์˜์‹ ๋ช…๋ฃŒ/์ •์ƒ ๋ฐ˜์‘ ๋ณด์ด๋Š” ์ƒํƒœ์—์„œ focal tonic-clonic seizure activity ๋ณด์ด๋Š” ๊ฒƒ.

F2. Treatment

2์ฐจ ํ•ญ๋‡Œ์ „์ฆ์ œ(AED) โ€” ๋ฒค์กฐ๋””์•„์ œํ•€ ์ดํ›„์˜ ์ฒ˜์น˜
BZD 1~2ํšŒ ํˆฌ์—ฌ์—๋„ ๊ฒฝ๋ จ์ด 5~10๋ถ„ ์ด์ƒ ์ง€์†๋˜๊ฑฐ๋‚˜, BZD๋กœ ๊ฒฝ๋ จ์„ ์†Œ์‹ค์‹œํ‚จ ์งํ›„๋ถ€ํ„ฐ ์žฌ๋ฐœ์ž‘ ์˜ˆ๋ฐฉ์„ ์œ„ํ•ด Non-BZD 2์ฐจ AED๋ฅผ ํˆฌ์—ฌ
์•ฝ๋ฌผ(์„ฑ๋ถ„๋ช…)
์„ฑ์ธ ํ‘œ์ค€ ์šฉ๋Ÿ‰
์ž„์ƒ์  ์žฅ์ 
์ฃผ์š” ์ฃผ์˜์‚ฌํ•ญ (Red Flag)
๋ ˆ๋น„ํ‹ฐ๋ผ์„ธํƒ (Levetiracetam / ์ผ€ํ”„๋ผ)
60 mg/kg (์ตœ๋Œ€ 4,500mg) 10~15๋ถ„ IV ์ฃผ์ž…
โ€ข ์‹ฌํ˜ˆ๊ด€ ๋ถ€์ž‘์šฉ ๊ฑฐ์˜ ์—†์Œ โ€ข ์•ฝ๋ฌผ ์ƒํ˜ธ์ž‘์šฉ ์ตœ์†Œํ™” โ€ข ํ˜„์žฌ ER์—์„œ ๊ฐ€์žฅ ์„ ํ˜ธ๋จ
โ€ข ์ •์‹ ํ–‰๋™ ์ด์ƒ ๋ฐ˜์‘(๋“œ๋ฌผ๊ฒŒ ๋™์š”, ๊ณต๊ฒฉ์„ฑ ๋“ฑ ๋ฐœํ˜„ ๊ฐ€๋Šฅ)
ํฌ์ŠคํŽ˜๋‹ˆํ† ์ธ (Fosphenytoin / ์‚ฌ๋ ™ํƒ€)
20 mg PE/kg (์ตœ๋Œ€ 1,500 mg PE) 150 mg PE/min ์ดํ•˜ ์ฃผ์ž…
โ€ข ํŽ˜๋‹ˆํ† ์ธ ์ „๊ตฌ์•ฝ๋ฌผ(Prodrug) โ€ข ์กฐ์ง ๊ดด์‚ฌ ์œ„ํ—˜ ๋‚ฎ์Œ (Purple glove syndrome ์˜ˆ๋ฐฉ)
โ€ข ์ €ํ˜ˆ์••, QT ์—ฐ์žฅ ๋ชจ๋‹ˆํ„ฐ๋ง ํ•„์ˆ˜ โ€ข ์ž„์‹ ๋ถ€ FDA Class D (์œ ํ•ด์„ฑ ์ž…์ฆ)
๋ฐœํ”„๋กœ์‚ฐ (Valproate / ๋ฐํŒŒ์ฝ”ํŠธ)
40 mg/kg (์ตœ๋Œ€ 3,000mg) 5~10๋ถ„ IV ์ฃผ์ž…
โ€ข ์ „์‹ ยท๋ถ€๋ถ„ ๋ฐœ์ž‘ ๋ชจ๋‘ ๊ฐ•๋ ฅํ•œ ํšจ๊ณผ
โ€ข ๊ธ‰์„ฑ ๊ฐ„๋ถ€์ „ ์ ˆ๋Œ€ ๊ธˆ๊ธฐ โ€ข ์†Œ์•„ ๋ฏธํ† ์ฝ˜๋“œ๋ฆฌ์•„ ์งˆํ™˜ ์ ˆ๋Œ€ ๊ธˆ๊ธฐ โ€ข ์ž„์‹ ๋ถ€ FDA Class X (๊ธฐํ˜• ์œ ๋ฐœ ์œ„ํ—˜)

(1) ๊ธฐ๋ณธ์ฒ˜์น˜

โ€ข
๋ชฉํ‘œ : 30๋ถ„ ๋‚ด์— seizure control
โ€ข
ABC (intubation ๊ณ ๋ ค), large bore IV, BST ํ™•์ธ, ๋ชจ๋‹ˆํ„ฐ๋ง (Saturation, ECG, ETCO2, U/O, ์ฒด์˜จ continously)
โ€ข
Glucose ํฌํ•จ, lab ์‹œํ–‰ (Mg, Ca, Lactate ํฌํ•จ metabloic pannel, Toxicology)
โ€ข
SE ์ค‘์—๋Š” tapping ๊ธˆ๊ธฐ (์„ธ๊ท ์„ฑ ์ˆ˜๋ง‰์—ผ ์˜์‹ฌ๋˜๋ฉด ํ•ญ์ƒ์ œ๋ถ€ํ„ฐ ๋จผ์ €)
โ€ข
๊ธฐ๋ณธ ์ˆ˜์•ก์€ normal saline (Phenytoin์ด dextrose์™€ ๊ฐ™์ด ์“ธ ์ˆ˜ ์—†์Œ)
โ€ข
์ €ํ˜ˆ๋‹น ํ™•์ธ ์‹œ IV DW ํˆฌ์•ฝ
โ€ข
Foley ์‚ฝ์ž…, NG tube๋„ aspiration ๋ฐฉ์ง€์— ๋„์›€.

(2) ํ•ญ๊ฒฝ๋ จ์ œ

โ€ข
IV lorazepam (initial TOC) or Diazepam โ†’ SE ์ง€์† ์‹œ : Fosphenytoin, Phenytoin, Levetiracetam, Valporate, lacosamide (20 ๋ถ„ ๋‚ด ์ถ”๊ฐ€
1.
BDZ ๊ณ„์—ด
โ€ข
Lorazepam - 2mg IV ( 0.1mg/kg) / Onset 3 ๋ถ„ / Duration ์ตœ๋Œ€ 12~24hrs - Diazepam๋ณด๋‹ค onset์€ ๋Šฆ์ง€๋งŒ duration์ด ๊ธธ์–ด์„œ (24hr vs 1hr) recur ์ ๋‹ค
โ€ข
IM lorazepam / buccal Midazolam / rectal diazepam ๊ฐ€๋Šฅ (์†Œ์•„์—์„œ buccal midazolam ๋” ์šฐ์ˆ˜)
โ€ข
์†Œ์•„, ์•Œ์ฝœ, barbiturate, ๊ธฐํƒ€ sedative ๋ณต์šฉ ์ค‘์ธ ์‚ฌ๋žŒ์€ ํ˜ธํก ์–ต์ œ, ํ˜ˆ์•• ์ €ํ•˜ ๋ฐœ์ƒ ๊ฐ€๋Šฅ
2.
Fosphenytoin
โ€ข
ํ˜ˆ์žฅ์—์„œ ํŽ˜๋‹ˆํ† ์ธ์œผ๋กœ ์ „ํ™˜
โ€ข
์šฉ๋งค์— ์—ํƒ„์˜ฌ, ํ”„๋กœํ•„๋ Œ ๊ธ€๋ฆฌ์ฝœ์ด ์—†์–ด์„œ infusion side effect์ ์Œ. ํŽ˜๋‹ˆํ† ์ธ๋ณด๋‹ค ์„ ํ˜ธ
โ€ข
Dosing - 20 PE/kg๋ฅผ 150 PE/min ์†๋„๋กœ 10~15 ๋ถ„ ๊ฐ„ ์ฃผ์ž… (PE : Penytoin Equivalents)
3.
Phenytoin
โ€ข
์šฉ๋งค์— propylene glycol์ด ์žˆ์–ด ์‹ฌ๊ทผ์–ต์ œ ๋ฐœ์ƒ ๊ฐ€๋Šฅ. ์†๋„ ์ฃผ์˜
โ€ข
๋ถ€ํ•˜์šฉ๋Ÿ‰ - 20mg/kg (๋ณดํ†ต 1000mg ์ด์ƒ )
โ€ข
์ฃผ์ž…์†๋„ - 25mg/min ์ดˆ๊ณผ๊ธˆ์ง€ (๋ณดํ†ต 1์‹œ๊ฐ„ ์ •๋„ ๊ฑธ๋ฆผ) โ†’ ์ดํ›„ ์ €ํ˜ˆ์•• ์—†์œผ๋ฉด 50mg/min์œผ๋กœ ์†๋„ ์˜ฌ๋ฆด ์ˆ˜ ์žˆ์Œ
โ€ข
์ฃผ์ž… ์‹œ 5~15 ๋งˆ๋‹ค ํ˜ˆ์••/ECG ๋ชจ๋‹ˆํ„ฐ๋ง ํ•„์š”. .์ฃผ์ž… ์ข…๋ฃŒ ํ›„ 1์‹œ๊ฐ„๊นŒ์ง€๋„ 15๋ถ„๋งˆ๋‹ค ํ™•์ธ
โ€ข
IM ๊ธˆ์ง€ / DW ์šฉ์•ก๊ณผ mix ๊ธˆ์ง€
โ€ข
2๋„/3 ๋ฐฉ์‹ค์ฐจ๋‹จ ํ™˜์ž ๊ธˆ๊ธฐ
โ€ข
์ €ํ˜ˆ์••/๋ถ€์ •๋งฅ ์‹œ ์ค‘๋‹จ. ์ดํ›„ subside๋˜๋ฉด lower rate๋กœ ์žฌ์‹œ์ž‘
4.
Valproic acid (Orfill 300mg/A)
โ€ข
20 mg/kg IV (์šฐ๋ฆฌ๋ณ‘์›์€ 30 mg/kg + N/S 100 mL mix ํ•˜์—ฌ 30๋ถ„๊ฐ„ Loading. OT/PT ํ™•์ธ)
โ€ข
ํšจ๊ณผ์ ์ด์ง€๋งŒ ์ƒ๊ธฐ ์•ฝ์ œ๋“ค๋ณด๋‹ค ๋ถ€์ž‘์šฉ ๋งŽ๋‹ค (ie; hepatic failure, pancreatitis) : ๊ฐ„์งˆํ™˜ ํ™˜์ž์—์„œ ๊ธˆ๊ธฐ
โ€ข
ํŽ˜๋‹ˆํ† ์ธ๊ณผ ์“ฐ๋ฉด ์•ˆ๋จ
5. Levetiracetam (Keppra, Q-pam 500mg/A)
โ€ข
๋ถ€์ž‘์šฉ ์ ๊ณ  ๋งค์šฐ ํšจ๊ณผ์ 
โ€ข
20 mg/kg IV (์šฐ๋ฆฌ๋ณ‘์›์€ 50mg/Kg + N/S 100 mL mixํ•˜์—ฌ 30๋ถ„๊ฐ„ Loading. Kidney function ํ™•์ธ)
โ€ข
SE์— ๋Œ€ํ•ด FDA ์Šน์ธ์€ ์•„์ง ์•ˆ ๋‚ฌ์ง€๋งŒ, SE์˜ first line์œผ๋กœ ๋งŽ์ด ์„ ํ˜ธ๋œ๋‹ค
โ€ข
๋ ˆ๋น„ํ‹ฐ๋ผ์„ธํƒ์€ SV2A(Synaptic Vesicle Glycoprotein 2A) ๋‹จ๋ฐฑ์งˆ์— ๊ฒฐํ•ฉํ•˜์—ฌ ์‹œ๋ƒ…์Šค ์†Œํฌ์˜ ์‹ ๊ฒฝ์ „๋‹ฌ๋ฌผ์งˆ ์œ ๋ฆฌ๋ฅผ ์กฐ์ ˆํ•จ์œผ๋กœ์จ ๊ณผํฅ๋ถ„์„ ์–ต์ œํ•ฉ๋‹ˆ๋‹ค. ๊ธฐ์ „์ด ๊ธฐ์กด AED์™€ ๋‹ฌ๋ผ ์•ฝ๋ฌผ ์ƒํ˜ธ์ž‘์šฉ์ด ๋งค์šฐ ์ ๊ณ , ์‹ฌํ˜ˆ๊ด€๊ณ„ ์˜ํ–ฅ์ด ๊ฑฐ์˜ ์—†์–ด ์ตœ๊ทผ ์‘๊ธ‰์‹ค์—์„œ 2์ฐจ AED์˜ ํ‘œ์ค€์œผ๋กœ ์ž๋ฆฌ ์žก๊ณ  ์žˆ์Šต๋‹ˆ๋‹ค. ESETT trial(Kapur J et al., NEJM 2019)์—์„œ ๋ ˆ๋น„ํ‹ฐ๋ผ์„ธํƒยทํฌ์ŠคํŽ˜๋‹ˆํ† ์ธยท๋ฐœํ”„๋กœ์‚ฐ 3์ œ ๋น„๊ต ์‹œ ์œ ํšจ์„ฑ ๋™๋“ฑ(P=0.68) ๊ฒฐ๊ณผ๊ฐ€ ํ™•์ธ๋˜์—ˆ์œผ๋ฉฐ, ์•ˆ์ „์„ฑ ํ”„๋กœํŒŒ์ผ ๋ฉด์—์„œ ๋ ˆ๋น„ํ‹ฐ๋ผ์„ธํƒ์ด ๊ฐ€์žฅ ์œ ๋ฆฌํ•ฉ๋‹ˆ๋‹ค.
6. Lacosamide
โ€ข
200 mg/IV per 15min.
โ€ข
์•„์ง ๋ฐ์ดํ„ฐ ๋ถ€์กฑ

F3. Refractory SE

โ€ข
์ ์ ˆํ•œ AED 2๊ฐœ ์ด์ƒ ์“ฐ๊ณ ๋„ seizure ์ง€์† ์‹œ. ๋ณดํ†ต 60๋ถ„ ๋„˜์–ด๊ฐ
โ€ข
SE ํ™˜์ž์˜ 31%๊ฐ€ refractory๋กœ ๋„˜์–ด๊ฐ
โ€ข
์‹ ๊ฒฝ๊ณผ consult / ICU care ํ•„์š” / ์•ฝ ์“ฐ๋‹ค ๋ณด๋ฉด ์ €ํ˜ˆ์••๋„ ์ž˜ ์™€์„œ ์Šน์••์ œ ์‚ฌ์šฉ ํ•„์š”ํ•  ์ˆ˜ ์žˆ์Œ
โ€ข
1st & 2nd line : ํ”„๋กœํฌํด, ๋ฏธ๋‹ค์กธ๋žŒ โ†’ 3rd line : Ketamine, Barbiturate

(1) Propofol (Anepol)

โ€ข
๋ฐ˜๊ฐ๊ธฐ ์งง์€ ๊ฒŒ ์žฅ์ 
โ€ข
2~10mg/kg/hr๋กœ ์‹œ์ž‘. seizure ๋ฉˆ์ถœ ๋•Œ ๊นŒ์ง€ infusion ์ฆ๋Ÿ‰ ๊ฐ€๋Šฅ
โ€ข
40mg/kg/hr ๋„˜์–ด๊ฐ€๋ฉด hemodynamic instability, propofol infusion SD ๋“ฑ ๋ฐœ์ƒ ๊ฐ€๋Šฅ

(2) Midazolam

โ€ข
0.05~0.4mg/kg/hr ๋กœ infusion ์‹œ์ž‘. seizure ๋ฉˆ์ถœ ๋•Œ๊นŒ์ง€ ์ฆ๋Ÿ‰ ๊ฐ€๋Šฅ
โ€ข
์‹ ์žฅ์•  ํ™˜์ž์—๊ฒŒ์„œ๋Š” ๋ฐฐ์ถœ์ด ๋Šฆ๋‹ค.

(3) Ketamine

โ‘  ์ตœํ›„์˜ ๋ฐฉ๋ฒ• โ‘ก ์‹ ๊ฒฝ ๋ณดํ˜ธ ํšจ๊ณผ โ‘ข 0.5~4.5 mg/kg bolus or infusion 5mg/kg/hr ์ตœ๋Œ€ ๊นŒ์ง€

(4) Barbiturates

โ€ข
BDZ full . ๋ฐ ๊ธฐํƒ€ ์•ฝ์ œ ์จ๋„ ์กฐ์ ˆ ์•ˆ ๋˜๋ฉด ๊ณ ๋ ค โ‘  Phenobarbital : 20mg/kg IV โ‘ก Pentobarbital

G. Special Populations

G1. HIV

(1) Mass lesion, encephalopathy, herpes zoster, toxoplasmosis, cryptococcus, neurosyphillis, meningitis ๊ฐ€ ํ”ํ•จ (2) ๊ฒ€์‚ฌ : Non CM BCT โ†’ Spinal tapping โ†’ Contrast CT or MRI ์ˆœ์œผ๋กœ ๊ณ ๋ ค

G2. Neurocysticercosis

(1) Tape worm (Taenia dolium)์˜ larval infection (2) ๊ฒฝ๋ จ์ด ๊ฐ€์žฅ ํ”ํ•œ ์ฆ์ƒ. ํŠนํžˆ ๊ฐœ๋„๊ตญ provoked seizure ์›์ธ ์ค‘ m/c (3) ๋‡Œ ์‹ค์งˆ ๋‚ด cysts ๋งŒ๋“ค๊ณ  1~2๋…„ ๊ฐ„ ๋ฌด์ฆ์ƒ โ†’ Fibrosis, Scarred, Calcification (4) ์˜์ƒ์†Œ๊ฒฌ : (๋Œ€๋ถ€๋ถ„ nondiagnostic ํ•˜๋””) 1~2cm cyst
+ ๋‚ด๋ถ€ mural nodule, calcification, ring like enhancement, hydrocephalus
(5) 80~90%๋Š” 6๊ฐœ์›” ๋‚ด ๋ณ‘๋ณ€ ์‚ฌ๋ผ์ง ํ•˜์ง€๋งŒ 20%๋Š” ๊ณ„์† ๊ฒฝ๋ จ (6) ๋ณดํ†ต AED monothreapy๋กœ ์ž˜ ์กฐ์ ˆ๋จ (7) ์น˜๋ฃŒ : Antiparasitics (praziquanterl, albendazole)์™€ steroid

G3. Pregnancy

(1) ๋Œ€๋ถ€๋ถ„์€ ์ด์ „์— ๊ฒฝ๋ จํ•˜๋˜ ํ™˜์ž (2) Eclampisa : GA 20์ฃผ ์ง€๋‚˜์„œ ๊ฒฝ๋ จ + ๊ณ ํ˜ˆ์••, ๋ถ€์ข…, ๋‹จ๋ฐฑ๋‡จ โ†’ Mg sulfate

G4. Alcohol Abuse

: Withdrawal seizure์— benzodiazepine์„ ์“ด๋‹ค
โ€ข
Rosen 8th, Ch 102, p.1376 seizure disorders (Tintinalli ์—๋Š” ์—†์œผ๋‚˜ ๊ณผ๊ฑฐ ๊ธฐ์ถœ) ๊ฒฝ๋ จ์ด ์Šค์Šค๋กœ ๋ฉˆ์ถ”๋Š” ๊ธฐ์ „ (1) Reflex inhibition (2) Synchrony์˜ ์†Œ์‹ค (3) ๋‰ด๋Ÿฐ์˜ ํ”ผ๋กœ (4) Acetylcholine๊ณผ GABA๊ฐ€ ์–ด๋А ๊ฒƒ์„ ์„ ํ˜ธํ•˜์—ฌ ์–ต์ œํ•˜๋Š”์ง€์— ๋Œ€ํ•œ ๊ตญ์†Œ์  ๊ท ํ˜•์˜ ๋ณ€ํ™”